Locations:
Phase 1 Breakfree-2 trial reports good safety and efficacy at week 26
Findings may have implications for understanding the disorders’ pathophysiology
Nearly one-fifth of such cases fulfill 2024 McDonald criteria based on biomarkers
Updates on this fast-evolving therapeutic landscape from a leading trialist
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Two research projects aim to enable more personalized MS care in this population
How to use? Consider starting during the acute attack and seek patient preferences for chronic use
Despite safety concerns and mixed trial results, experts see potential for this indication
Study looked at mobility measures and safety
Study shows short-term behavioral training can yield objective and subjective gains
Mixed results from phase 2 CALLIPER trial of novel dual-action compound
Advertisement
Advertisement
Search